JNJRefreshed on 2026-03-24 using Johnson & Johnson FY2025 reporting and March 2026 market-cap data after the consumer-health separation.

Johnson & Johnson

Diversified health-care company focused on Innovative Medicine and MedTech after the Kenvue consumer-health separation.

CompaniesMarketCap Product analyses

Metadata

Where this company sits

Ticker: JNJ
Rank snapshot: ≈ 19
Sector: Health Care
Industry: Pharma & MedTech
Region: United States
Index: S&P 500 · Top 20 by market cap

Metrics

Scoring view

Every metric is paired with a short rationale. The numbers are deliberate, not divine.

Moat

9.0/10

The company combines large-scale drug R&D, device platforms, global distribution, regulatory execution, and strong cash generation across multiple health-care categories, which creates a durable incumbent position.

Decentralizability

3.0/10

Most of the portfolio depends on patent protection, clinical evidence, regulated manufacturing, and hospital or specialist distribution, which limits near-term replacement by open or decentralized systems.

Profitability

8.0/10

Johnson & Johnson reported $26.2 billion in adjusted net earnings and about $19.7 billion in free cash flow for 2025, indicating strong underlying profitability.

Price / Earnings

22.5x

MacroTrends listed Johnson & Johnson's trailing P/E ratio at 22.54 as of March 12, 2026; this is market-data-derived and can move daily.

Market cap

$585.6B

CompaniesMarketCap listed Johnson & Johnson at approximately $585.58 billion of market capitalization in March 2026, ranking it 19th globally.

Freed-up capital potential

$41.7B

Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.

Narrative

Why the company matters

A short editorial overview plus the current thesis on moat strength and decentralization pressure.

Portfolio Shape

Johnson & Johnson now presents itself as a two-segment health-care platform spanning Innovative Medicine and MedTech, with strategic concentration in oncology, immunology, neuroscience, cardiovascular, surgery, and vision.

Its 2025 annual report frames that combination of drug development, device franchises, clinical evidence generation, and global manufacturing as a differentiated scale advantage versus narrower pharma or medtech peers.

Current Financial Snapshot

Johnson & Johnson reported $94.2 billion of 2025 sales, adjusted net earnings of $26.2 billion, and nearly $19.7 billion of free cash flow, indicating a still very profitable incumbent despite patent-loss pressure around STELARA.

As of March 2026, CompaniesMarketCap placed Johnson & Johnson at roughly $585.6 billion in market value and rank 19 globally, consistent with its inclusion in the S&P 500 top-20 market-cap snapshot used for this registry refresh.

Moat reading

Johnson & Johnson's moat is built on regulatory expertise, a broad commercial footprint, deep clinician relationships, manufacturing scale, and a portfolio that spans high-value medicines and procedure-linked devices. Those advantages compound because approvals, reimbursement pathways, post-market surveillance, and hospital procurement all favor incumbents with capital and operating history.

The moat is not invulnerable. Patent expirations, device-category competition, and reimbursement pressure can erode product-level economics, but the company's scale, cash generation, and ability to redeploy capital across therapy areas and device categories keep the enterprise moat strong even when individual franchises mature.

Decentralization reading

Johnson & Johnson is relatively hard to decentralize in the near term because much of its value sits inside patented therapeutics, biologics manufacturing, regulated clinical evidence, and procedure-integrated medtech platforms that still require heavy compliance and capital. That makes broad replacement by open systems slower than in software or media.

The more realistic decentralizing pressure comes at the edges: open science in drug discovery, generic or cooperative manufacturing for mature therapies, open-hardware medical tooling, and distributed fabrication for simpler devices and supplies. Those mechanisms can chip away at portions of the value chain, but they do not yet amount to a full-stack substitute for J&J's current portfolio.

Products

Where the moat actually touches users

These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.

2 disruption concepts tracked0 documented exceptions

Innovative Medicine portfolio

pharmaceuticals

1 concept

Johnson & Johnson's Innovative Medicine segment spans oncology, immunology, neuroscience, and cardiopulmonary therapies, with multiple blockbuster products and a large late-stage pipeline.

Open analysis

MedTech portfolio

medical-devices

1 concept

Johnson & Johnson's MedTech segment covers cardiovascular intervention, surgery, robotics, wound closure, and vision products sold into clinician and hospital workflows.

Open analysis

Technology waves

Strategic lenses

These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.

Additive manufacturing

3D plastic and metal printing keep collapsing the minimum viable factory into something much smaller, cheaper, and more local.

• Hardware moats tied to long-tail spare parts and custom enclosures should weaken over time.
• Localized production improves resilience for niche components and repair ecosystems.
• Software plus design-file control can become as important as physical inventory control.

Microfactories and automated mini-home production

Small, software-defined manufacturing cells could make localized production less eccentric and more default.

• Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
• Logistics moats still matter, but their margin for arrogance should narrow.
• Open-source production recipes can pressure both price and product differentiation.

Paper trail